GILT/IFI30 Antibody (MaP.IP30)

• Reactivity: Hu
• Applications: Flow, Func, ICC/IF, IP
• Clone: MaP.IP30
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: 0.1 mg/ml

GILT/IFI30 Antibody (MaP.IP30) Summary

• Description: Novus Biologicals Mouse GILT/IFI30 Antibody (MaP.IP30) (NBP3-11217) is a monoclonal antibody validated for use in Flow, ICC/IF and IP. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: Partial purified IP30 (purified from human B-LCL)
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: IFI30
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry
  • Functional
  • Immunocytochemistry/ Immunofluorescence
  • Immunoprecipitation
• Application Notes: For Flow Cytometry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 2ug/250000 cells.

Packaging, Storage & Formulations

• Storage: Store at 4C.
• Buffer: 0.2 um filtered solution in PBS, 0.1% BSA
• Preservative: 0.02% Sodium Azide
• Concentration: 0.1 mg/ml
• Purity: Protein G purified

Alternate Names for GILT/IFI30 Antibody (MaP.IP30)

• EC 1.8
• Gamma-interferon-inducible protein IP-30
• GILT
• GILTgamma-interferon-inducible lysosomal thiol reductase
• IFI30
• IFI-30
• interferon, gamma-inducible protein 30
• IP30
• IP30interferon gamma-inducible protein 30 preproprotein
• Legumaturain
• MGC32056

Background

Antibodies derived from clone MAP.IP30 recognize human gamma-interferon-inducible lysosomal thiol reductase (GILT). GILT facilitates major histocompatibility complex (MHC) class II-restricted processing through reduction of protein disulfide bonds in the endocytic pathway. GILT can also facilitate the transfer of disulfide-containing antigens into the cytosol, enhancing their cross-presentation by MHC class I. Human GILT consists of 261 amino acids with a 37 amino acid signal sequence and a 224 amino acid precursor form. In general, the 35 kDa precursor is tagged with mannose-6- phosphate (M6P) residues and transported to the endocytic pathway via the M6P receptor (M6PR). A small fraction of the precursor is secreted as a disulfide-linked dimer. In early endosomes, N- and C-terminal pro-peptides are cleaved to generate a 28 kDa mature form. The mature form of GILT is localized to late endosomes and lysosomes and has maximal reductase activity at the acidic pH found in these compartments. GILT is constitutively expressed in professional antigen presenting cells (APC). The constitutive expression of GILT in APCs is likely to account for enhanced reduction of proteins in the late endosomal, lysosomal, and phagosomal compartments. A combination of GILT-mediated reduction and proteolysis in the these compartments can enhance the generation of class II epitopes as well as facilitate the translocation of internalized antigens into the cytosol for proteosomal processing and cross-presentation. The protein is also constitutively expressed in thymocytes, mature T cells, and some fibroblasts. IFN-g plays is the key factor in inducing expression of MHC class II and other components of the class II-restricted processing pathway. IFN-g signals through a specific cell surface receptor followed by activation of JAK/STAT1 signalling.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: IFI30